ZA200803236B - Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders - Google Patents
Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disordersInfo
- Publication number
- ZA200803236B ZA200803236B ZA200803236A ZA200803236A ZA200803236B ZA 200803236 B ZA200803236 B ZA 200803236B ZA 200803236 A ZA200803236 A ZA 200803236A ZA 200803236 A ZA200803236 A ZA 200803236A ZA 200803236 B ZA200803236 B ZA 200803236B
- Authority
- ZA
- South Africa
- Prior art keywords
- adenosine
- extra
- treatment
- receptor antagonists
- movement disorders
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- 208000027776 Extrapyramidal disease Diseases 0.000 title 1
- 208000016285 Movement disease Diseases 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/249,796 US20060128694A1 (en) | 2002-12-19 | 2005-10-13 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803236B true ZA200803236B (en) | 2009-03-25 |
Family
ID=37719335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200803236A ZA200803236B (en) | 2005-10-13 | 2008-04-11 | Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060128694A1 (xx) |
| EP (1) | EP2001511A1 (xx) |
| JP (1) | JP2009511588A (xx) |
| CN (1) | CN101325974A (xx) |
| AU (1) | AU2006304102A1 (xx) |
| BR (1) | BRPI0617415A2 (xx) |
| CA (1) | CA2625859A1 (xx) |
| NO (1) | NO20082175L (xx) |
| TW (1) | TW200800263A (xx) |
| WO (1) | WO2007047293A1 (xx) |
| ZA (1) | ZA200803236B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| BRPI0411120A (pt) | 2003-06-10 | 2006-07-18 | Kyowa Hakko Kogyo Kk | método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina |
| US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
| WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| IL284745B1 (en) | 2019-01-11 | 2025-04-01 | Omeros Corp | Compositions containing 174GPR inhibitor compounds and their uses for the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| CA2116967C (en) * | 1992-07-08 | 2003-08-19 | Fumio Suzuki | Antidepressants |
| BR0306919A (pt) * | 2002-01-28 | 2004-11-09 | Kyowa Hakko Kogyo Kk | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento |
| ATE490775T1 (de) * | 2002-12-19 | 2010-12-15 | Schering Corp | Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms |
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| DE602004021250D1 (de) * | 2003-04-23 | 2009-07-09 | Schering Corp | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4-triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten |
| DE602005020127D1 (de) * | 2004-04-21 | 2010-05-06 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| AU2005264960A1 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Antagonizing an adenosine A2A receptor to amelioriate one or more components of addictive behavior |
| JP2008524330A (ja) * | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト |
-
2005
- 2005-10-13 US US11/249,796 patent/US20060128694A1/en not_active Abandoned
-
2006
- 2006-10-11 WO PCT/US2006/039689 patent/WO2007047293A1/en active Application Filing
- 2006-10-11 CA CA002625859A patent/CA2625859A1/en not_active Abandoned
- 2006-10-11 EP EP06825743A patent/EP2001511A1/en not_active Withdrawn
- 2006-10-11 BR BRPI0617415-9A patent/BRPI0617415A2/pt not_active Application Discontinuation
- 2006-10-11 JP JP2008535638A patent/JP2009511588A/ja active Pending
- 2006-10-11 AU AU2006304102A patent/AU2006304102A1/en not_active Abandoned
- 2006-10-11 CN CNA2006800463473A patent/CN101325974A/zh active Pending
- 2006-10-12 TW TW095137566A patent/TW200800263A/zh unknown
-
2008
- 2008-04-11 ZA ZA200803236A patent/ZA200803236B/xx unknown
- 2008-05-09 NO NO20082175A patent/NO20082175L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200800263A (en) | 2008-01-01 |
| AU2006304102A1 (en) | 2007-04-26 |
| BRPI0617415A2 (pt) | 2011-07-26 |
| EP2001511A1 (en) | 2008-12-17 |
| CA2625859A1 (en) | 2007-04-26 |
| CN101325974A (zh) | 2008-12-17 |
| NO20082175L (no) | 2008-07-11 |
| US20060128694A1 (en) | 2006-06-15 |
| WO2007047293A1 (en) | 2007-04-26 |
| JP2009511588A (ja) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE039348T2 (hu) | A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra | |
| ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| ZA200802552B (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
| ZA200800353B (en) | Pyrazine derivatives useful as adenosine receptor antagonists | |
| IL184425A0 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| IL192426A0 (en) | Prokineticin 2 receptor antagonists | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| IL179462A0 (en) | Use of the receptor gpr86 | |
| IL192424A0 (en) | Prokineticin 1 receptor antagonists | |
| ZA200709147B (en) | Pyrimidindione derivatives as prokineticin 2 receptor antagonists | |
| SI1951661T1 (sl) | Antagonisti glukagonskega receptorja priprava interapevtske uporabe | |
| ZA200702130B (en) | Memantine for the treatment of childhood behavioral disorders | |
| IL190913B (en) | Preparations for the treatment of sweating disorders | |
| PL1951658T3 (pl) | Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne | |
| ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
| ZA200710699B (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | |
| ZA200803236B (en) | Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders | |
| IL178622A0 (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| IL238702A0 (en) | History of tetrazole-modified arylamides and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists | |
| ZA200804500B (en) | Methods and compositions for the treatment of gastro-intestinal disorders | |
| PT1922309E (pt) | Derivados de n-fenil-2-pirimidina-amina e processo para a sua preparação | |
| PL1881830T3 (pl) | Pochodne 4-fenylo-5-okso-1,4,5,6,7,8-heksahydrochinoliny do leczenia niepłodności | |
| HK1102298A1 (en) | Backrest supporting posture of infants and supporting device for the infants using the said backrest | |
| EP1751175A4 (en) | ANTAGONISTS OF THE INTERLEUKIN-1 RECEPTOR, COMPOSITIONS AND TREATMENT PROCEDURES | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists |